Core Viewpoint - China Nuclear Industry's subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., has received approval for clinical trial application of its self-developed drug "Injectable Boron [B] Falan" for BNCT, marking a significant advancement in cancer treatment [1] Group 1: Product Development - The drug targets head and neck tumors that are resistant to radiotherapy and chemotherapy, offering significant clinical advantages [1] - Treatment requires only 1-2 sessions and has low toxicity and side effects, representing a breakthrough in precision medicine for cancer [1] Group 2: Clinical and Strategic Implications - The approval signifies a breakthrough in the collaborative research and development of BNCT drugs and devices, entering a new phase of clinical transformation [1] - This development aligns with China's "Healthy China" strategy, injecting new momentum into precision cancer treatment and contributing a "Chinese solution" to global cancer therapy [1]
中国同辐(01763)附属公司中核海得威BNCT硼药获批临床